Andrea S. Blevins Primeau

The combination of tafasitamab with lenalidomide and rituximab demonstrated efficacy in high-risk subgroups of patients with relapsed/refractory (R/R) follicular lymphoma (FL), according to a post hoc analysis of the inMIND trial presented at the EHA 2026 Congress.

CPX-351 treatment resulted in improved overall survival (OS) among patients with myelodysplastic-related (MR) acute myeloid leukemia (AML) who underwent hematopoietic transplantation (HCT), according to analysis of a phase 3 trial published in Blood Advances.

More than one-quarter of surveyed European countries did not have access to CD19 chimeric antigen receptor (CAR) T-cell therapy for pediatric patients with B-cell acute lymphoblastic leukemia (B-ALL), according to the result of the IMPACT study published in JCO Global Oncology.

Treatment-naïve patients with chronic lymphocytic leukemia (CLL) who developed diffuse large B-cell lymphoma (DLBCL)-type Richter transformation (DLBCL-RT) demonstrated longer time to next treatment or death (TTNTd) and overall survival (OS) compared with patients who previously received CLL-related therapy, according to results from a large observational study published in the British Journal of Haematology.

The greatest progression-free survival (PFS) benefit among patients with previously untreated chronic lymphocytic leukemia (CLL) was fixed-duration triplet therapy with venetoclax plus obinutuzumab (GV) and ibrutinib (GIV), according to a 5-year updated analysis from the CLL13/GAIA trial published in the journal Blood.

In collaboration with the North American Society of Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN) and the American Society of

The addition of rituximab maintenance therapy after completion of ibrutinib -containing therapy resulted in longer progression-free survival (PFS) among younger patients with mantle cell lymphoma (MCL), according to a secondary analysis of the TRIANGLE trial published in the Journal of Clinical Oncology. However, rituximab maintenance therapy was associated with higher rates of grade 3-5 infections.

Long-term follow-up from the phase 2 ACE-WM-001 trial demonstrated that the efficacy and safety of acalabrutinib was maintained over 5 years among patients with Waldenström macroglobulinemia (WM), according to a report published in Blood Advances.

Results from a real-world study demonstrated that the efficacy and safety of lisocabtagene maraleucel (liso-cel) among patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) was consistent with that observed in prior clinical trials, according to a report published in the journal Blood.

Patients with primary immune thrombocytopenia (ITP) treated with ianalumab plus eltrombopag reported improvements in patient-reported outcomes (PROs) in symptoms, fatigue, bother, and activity scales domains, according to results from the phase 3 VAYHIT2 trial presented at the Society of Hematology Oncology 2026 Annual Meeting.